Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $53,597.60 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 560 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $95.71, for a total value of $53,597.60. Following the completion of the transaction, the senior vice president directly owned 14,752 shares of the company’s stock, valued at approximately $1,411,913.92. The trade was a 3.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.23, for a total value of $872,403.57.
• On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00.
• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The stock was sold at an average price of $84.63, for a total value of $846,215.37.
• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The shares were sold at an average price of $80.95, for a total value of $128,467.65.

Oruka Therapeutics Stock Up 4.5%

Shares of ORKA stock opened at $97.73 on Friday. The firm has a market cap of $6.47 billion, a price-to-earnings ratio of -48.14 and a beta of -0.34. Oruka Therapeutics, Inc. has a 12 month low of $14.89 and a 12 month high of $115.51. The stock has a 50-day moving average price of $96.24 and a 200 day moving average price of $73.64.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Sell-side analysts predict that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Institutional Trading of Oruka Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Algert Global LLC lifted its stake in Oruka Therapeutics by 3.5% in the 2nd quarter. Algert Global LLC now owns 5,380 shares of the company’s stock valued at $512,000 after acquiring an additional 180 shares in the last quarter. Nykredit A S acquired a new stake in shares of Oruka Therapeutics in the second quarter valued at approximately $29,000. AlphaCentric Advisors LLC raised its holdings in shares of Oruka Therapeutics by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after purchasing an additional 626 shares during the last quarter. Orion Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the second quarter valued at approximately $91,000. Finally, PNC Financial Services Group Inc. lifted its position in shares of Oruka Therapeutics by 119.7% in the first quarter. PNC Financial Services Group Inc. now owns 3,186 shares of the company’s stock worth $156,000 after purchasing an additional 1,736 shares in the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

Analyst Ratings Changes

ORKA has been the subject of a number of recent analyst reports. Guggenheim reaffirmed a “buy” rating and issued a $200.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. BTIG Research reiterated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Piper Sandler reissued an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Finally, Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Oruka Therapeutics has an average rating of “Moderate Buy” and an average target price of $133.00.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.